Micha Maeder

Dr. Micha Maeder

Division of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in Chest
Verified
Journal Article
Closed access
PDF file
MMMicha Maeder
Micha Maeder
TFThomas Fehr
Thomas Fehr
HRHans Rickli
Hans Rickli
PAPeter Ammann
Peter Ammann

28 December 2015 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
SRSebastian Rogowski
Sebastian Rogowski
MMMicha Maeder
Micha Maeder
DWDaniel Weilenmann
Daniel Weilenmann
PHPhilipp K. Haager
Philipp K. Haager
PAPeter Ammann
Peter Ammann
HRHans Rickli
Hans Rickli

1 November 2004 in JACC
Verified
Journal Article
Closed access
MMMicha Maeder
Micha Maeder
MKMaja Klein
Maja Klein
TFThomas Fehr
Thomas Fehr
HRHans Rickli
Hans Rickli

1 June 2005 in International Journal of Cardiology
Verified
Journal Article
Closed access
MMMicha Maeder
Micha Maeder
PAPeter Ammann
Peter Ammann
WAWalter Angehrn
Walter Angehrn
HRHans Rickli
Hans Rickli

23 May 2018 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
MMMicha Maeder
Micha Maeder
LWLukas Weber
Lukas Weber
MBMarc Buser
Marc Buser
MGMarc Gerhard
Marc Gerhard
PHPhilipp K. Haager
Philipp K. Haager
HRHans Rickli
Hans Rickli
In patients with aortic and/or mitral valve disease the presence of pulmonary hypertension (PH) indicates a decompensated state of the disease with left ventricular and left atrial dysfunction and exhausted compensatory mechanism, i.e., a state of heart failure. Pulmonary hypertension in this context is the consequence of the backwards transmission of elevated left atrial pressure. In this form of PH, pulmonary vascular resistance is initially normal (isolated post-capillary PH). Depending on the extent and chronicity of left atrial pressure elevation additional pulmonary vascular remodeling may occur (combined pre- and post-capillary PH). Mechanical interventions for the correction of valve disease often but not always reduce pulmonary pressures. However, the reduction in pulmonary pressures is often modest, and persistent PH in these patients is common and a marker of poor prognosis. In the present review we discuss the pathophysiology and clinical impact of PH in patients with aortic and mitral valve disease, the comprehensive non-invasive and invasive diagnostic approach required to define treatment of PH, and recent insights from mechanistic studies, registries and randomized studies, and we provide an outlook regarding gaps in evidence, future clinical challenges, and research opportunities in this setting.

1 March 2016 in Vascular Health and Risk Management
Verified
Journal Article
Open access
PDF file
MMMicha Maeder
Micha Maeder
OSOtto Schoch
Otto Schoch
HRHans Rickli
Hans Rickli
Obstructive sleep apnea (OSA) is associated with cardiovascular risk factors, cardiovascular diseases, and increased mortality. Epidemiological studies have established these associations, and there are now numerous experimental and clinical studies which have provided information on the possible underlying mechanisms. Mechanistic proof-of-concept studies with surrogate endpoints have been performed to demonstrate that treatment of OSA by continuous positive airway pressure (CPAP) has the potential to reverse or at least to attenuate not only OSA but also the adverse cardiovascular effects associated with OSA. However, no randomized studies have been performed to demonstrate that treatment of OSA by CPAP improves clinical outcomes in patients with cardiovascular risk factors and/or established cardiovascular disease and concomitant OSA. In the present review, we summarize the current knowledge on the role of OSA as a potential cardiovascular risk factor, the impact of OSA on cardiac function, the role of OSA as a modifier of the course of cardiovascular diseases such as coronary artery disease, atrial fibrillation, and heart failure, and the insights from studies evaluating the impact of CPAP therapy on the cardiovascular features associated with OSA.